<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04776850</url>
  </required_header>
  <id_info>
    <org_study_id>2020-0952</org_study_id>
    <secondary_id>NCI-2021-00365</secondary_id>
    <secondary_id>2020-0952</secondary_id>
    <nct_id>NCT04776850</nct_id>
  </id_info>
  <brief_title>Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies</brief_title>
  <official_title>Pre-Transplant Immunosuppression and Related Haploidentical Hematopoietic Cell Transplantation for Patients With Severe Hemoglobinopathies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial studies the effect of pre-transplant immunosuppression (PTIS) and donor&#xD;
      stem cell transplant in treating patients with severe blood diseases (hemoglobinopathies).&#xD;
      PTIS helps prepare the body for the transplant and lowers the risk of developing graft versus&#xD;
      host disease (GVHD). Hematopoietic cells are found in the bone marrow and produce blood&#xD;
      cells. Hematopoietic cell transplantation (HCT) injects healthy hematopoietic cells into the&#xD;
      body to support blood cell production. PTIS and HCT may help to control severe&#xD;
      hemoglobinopathies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To estimate event-free survival (EFS) at 2-years post HCT.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Assess event-free survival (EFS) at 100 days and 1 year post HCT. II. Assess overall&#xD;
      survival (OS) at 100 days and 1 year post HCT. III. 30-day transplant-related mortality&#xD;
      (TRM). IV. Time to platelet and neutrophil engraftment. V. Rate of graft failure (primary and&#xD;
      secondary) through day 100. VI. Incidence of acute graft-versus-host disease (aGVHD) by day&#xD;
      100. VII. Incidence of chronic graft-versus-host disease (cGVHD) by 1 year and 2 years.&#xD;
&#xD;
      VIII. Rate of grade II or greater organ toxicity through day 100. IX. Incidence of hepatic&#xD;
      sinusoidal obstruction syndrome (SOS) by day 100. X. Incidence of central nervous system&#xD;
      (CNS) toxicities including posterior reversible encephalopathy syndrome (PRES) by day 100.&#xD;
&#xD;
      XI. Incidence of infectious complications through day 100.&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      I. Effect of HCT on clinical and laboratory manifestations of hemoglobinopathies by 1 and 2&#xD;
      years after HCT.&#xD;
&#xD;
      II. Assess the pharmacokinetic profile of busulfan and thymoglobulin to better understand&#xD;
      post-transplant outcomes.&#xD;
&#xD;
      III. Assess immune reconstitution kinetics post HCT.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      DONOR-SPECIFIC ANTI-HLA DESENSITIZATION: Patients with donor-specific anti-HLA antibody&#xD;
      titers &gt;= 1:3,000 at the start of PTIS receive rituximab intravenously (IV) on days -69, -41,&#xD;
      -28, and -13 and bortezomib IV over less than 1 minute on days -68, -65, -40, and -37 in the&#xD;
      absence of unacceptable toxicity. Patients with donor-specific anti-HLA antibody titers &gt;&#xD;
      1:15,000 at the start of PTIS receive receive rituximab IV on days -69, -41, -28, and -13 and&#xD;
      bortezomib IV over less than 1 minute on days -68, -65, -62, -58, -40, -37, -34, and -31 in&#xD;
      the absence of unacceptable toxicity. Patients with donor-specific anti-HLA antibody titers &gt;&#xD;
      1:5,000 at the start of conditioning may also undergo plasmapheresis on day -12.&#xD;
&#xD;
      PTIS: Patients receive fludarabine phosphate (fludarabine) IV over 1 hour and dexamethasone&#xD;
      IV over less than 1 minute on days -68 to -64 and days -40 to -36 in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      CONDITIONING: Patients receive lapine T-lymphocyte immune globulin (rATG) IV over 4-6 hours&#xD;
      on days -12 to -10, fludarabine phosphate IV over 1 hour on days -8 to -4, and busulfan IV&#xD;
      over 2 hours on days -7 to -4 in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      TRANSPLANT: Patients undergo HCT on day 0.&#xD;
&#xD;
      GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 2-3 hours on days 3 and 4 in the&#xD;
      absence of unacceptable toxicity. Beginning on day 5, patients also receive tacrolimus IV&#xD;
      continuously daily and then orally (PO) twice daily (BID) at the discretion of the treating&#xD;
      physician for up to 12 months, and mycophenolate mofetil IV or PO BID up to day 60 in the&#xD;
      absence of unacceptable toxicity.&#xD;
&#xD;
      After completion of HCT, patients are followed up periodically for up to 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 29, 2020</start_date>
  <completion_date type="Anticipated">October 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>At 2 years post-hematopoietic cell transplantation (HCT)</time_frame>
    <description>EFS is defined as survival time following HCT without a qualifying event. Will be summarized by the Kaplan-Meier method with 95% confidence intervals.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>Up to 100 days post-HCT</time_frame>
    <description>EFS is defined as survival time following HCT without a qualifying event. Will be summarized by the Kaplan-Meier method with 95% confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>Up to 1 year post-HCT</time_frame>
    <description>EFS is defined as survival time following HCT without a qualifying event. Will be summarized by the Kaplan-Meier method with 95% confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 100 days post-HCT</time_frame>
    <description>Will be summarized by the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 1 year post-HCT</time_frame>
    <description>Will be summarized by the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplant-related mortality</measure>
    <time_frame>Up to 30 days post-HCT</time_frame>
    <description>Will be summarized by the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to platelet and neutrophil engraftment</measure>
    <time_frame>Up to 2 years post-HCT</time_frame>
    <description>Will be estimated using the method of Gooley et al.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of graft failure (primary and secondary)</measure>
    <time_frame>Up to 100 days post-HCT</time_frame>
    <description>Will be estimated using the method of Gooley et al.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute graft-versus-host disease</measure>
    <time_frame>Up to 100 days post-HCT</time_frame>
    <description>Will be estimated using the method of Gooley et al.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of chronic graft-versus-host disease</measure>
    <time_frame>Up to 1 year post-HCT</time_frame>
    <description>Will be estimated using the method of Gooley et al.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of chronic graft-versus-host disease</measure>
    <time_frame>Up to 2 years post-HCT</time_frame>
    <description>Will be estimated using the method of Gooley et al.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of grade II or greater organ toxicity</measure>
    <time_frame>Up to 100 days post-HCT</time_frame>
    <description>Will be reported as counts with percentages.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hepatic sinusoidal obstruction syndrome</measure>
    <time_frame>Up to 100 days post-HCT</time_frame>
    <description>Will be reported as counts with percentages.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of central nervous system toxicities including posterior reversible encephalopathy syndrome</measure>
    <time_frame>Up to 100 days post-HCT</time_frame>
    <description>Will be reported as counts with percentages.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of infectious complications</measure>
    <time_frame>Up to 100 days post-HCT</time_frame>
    <description>Will be reported as counts with percentages.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Beta Thalassemia Major</condition>
  <condition>Sickle Beta 0 Thalassemia</condition>
  <condition>Sickle Beta Plus Thalassemia</condition>
  <condition>Sickle Beta Thalassemia</condition>
  <condition>Sickle Cell Disease</condition>
  <condition>Sickle Cell-SS Disease</condition>
  <arm_group>
    <arm_group_label>Treatment (PTIS, HCT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Detailed Description.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (PTIS, HCT)</arm_group_label>
    <other_name>[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid</other_name>
    <other_name>LDP 341</other_name>
    <other_name>MLN341</other_name>
    <other_name>PS-341</other_name>
    <other_name>PS341</other_name>
    <other_name>Velcade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (PTIS, HCT)</arm_group_label>
    <other_name>1, 4-Bis[methanesulfonoxy]butane</other_name>
    <other_name>BUS</other_name>
    <other_name>Bussulfam</other_name>
    <other_name>Busulfanum</other_name>
    <other_name>Busulfex</other_name>
    <other_name>Busulphan</other_name>
    <other_name>CB 2041</other_name>
    <other_name>CB-2041</other_name>
    <other_name>Glyzophrol</other_name>
    <other_name>GT 41</other_name>
    <other_name>GT-41</other_name>
    <other_name>Joacamine</other_name>
    <other_name>Methanesulfonic Acid Tetramethylene Ester</other_name>
    <other_name>Methanesulfonic acid, tetramethylene ester</other_name>
    <other_name>Mielucin</other_name>
    <other_name>Misulban</other_name>
    <other_name>Misulfan</other_name>
    <other_name>Mitosan</other_name>
    <other_name>Myeleukon</other_name>
    <other_name>Myeloleukon</other_name>
    <other_name>Myelosan</other_name>
    <other_name>Mylecytan</other_name>
    <other_name>Myleran</other_name>
    <other_name>Sulfabutin</other_name>
    <other_name>Tetramethylene Bis(methanesulfonate)</other_name>
    <other_name>Tetramethylene bis[methanesulfonate]</other_name>
    <other_name>WR-19508</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (PTIS, HCT)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamide Monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (PTIS, HCT)</arm_group_label>
    <other_name>Aacidexam</other_name>
    <other_name>Adexone</other_name>
    <other_name>Aknichthol Dexa</other_name>
    <other_name>Alba-Dex</other_name>
    <other_name>Alin</other_name>
    <other_name>Alin Depot</other_name>
    <other_name>Alin Oftalmico</other_name>
    <other_name>Amplidermis</other_name>
    <other_name>Anemul mono</other_name>
    <other_name>Auricularum</other_name>
    <other_name>Auxiloson</other_name>
    <other_name>Baycadron</other_name>
    <other_name>Baycuten</other_name>
    <other_name>Baycuten N</other_name>
    <other_name>Cortidexason</other_name>
    <other_name>Cortisumman</other_name>
    <other_name>Decacort</other_name>
    <other_name>Decadrol</other_name>
    <other_name>Decadron</other_name>
    <other_name>Decadron DP</other_name>
    <other_name>Decalix</other_name>
    <other_name>Decameth</other_name>
    <other_name>Decasone R.p.</other_name>
    <other_name>Dectancyl</other_name>
    <other_name>Dekacort</other_name>
    <other_name>Deltafluorene</other_name>
    <other_name>Deronil</other_name>
    <other_name>Desamethasone</other_name>
    <other_name>Desameton</other_name>
    <other_name>Dexa-Mamallet</other_name>
    <other_name>Dexa-Rhinosan</other_name>
    <other_name>Dexa-Scheroson</other_name>
    <other_name>Dexa-sine</other_name>
    <other_name>Dexacortal</other_name>
    <other_name>Dexacortin</other_name>
    <other_name>Dexafarma</other_name>
    <other_name>Dexafluorene</other_name>
    <other_name>Dexalocal</other_name>
    <other_name>Dexamecortin</other_name>
    <other_name>Dexameth</other_name>
    <other_name>Dexamethasone Intensol</other_name>
    <other_name>Dexamethasonum</other_name>
    <other_name>Dexamonozon</other_name>
    <other_name>Dexapos</other_name>
    <other_name>Dexinoral</other_name>
    <other_name>Dexone</other_name>
    <other_name>Dinormon</other_name>
    <other_name>Dxevo</other_name>
    <other_name>Fluorodelta</other_name>
    <other_name>Fortecortin</other_name>
    <other_name>Gammacorten</other_name>
    <other_name>Hexadecadrol</other_name>
    <other_name>Hexadrol</other_name>
    <other_name>Lokalison-F</other_name>
    <other_name>Loverine</other_name>
    <other_name>Methylfluorprednisolone</other_name>
    <other_name>Millicorten</other_name>
    <other_name>Mymethasone</other_name>
    <other_name>Orgadrone</other_name>
    <other_name>Spersadex</other_name>
    <other_name>TaperDex</other_name>
    <other_name>Visumetazone</other_name>
    <other_name>ZoDex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine Phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (PTIS, HCT)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
    <other_name>SH T 586</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hematopoietic Cell Transplantation</intervention_name>
    <description>Undergo HCT</description>
    <arm_group_label>Treatment (PTIS, HCT)</arm_group_label>
    <other_name>HCT</other_name>
    <other_name>Hematopoietic Stem Cell Transplantation</other_name>
    <other_name>HSCT</other_name>
    <other_name>Stem Cell Transplant</other_name>
    <other_name>stem cell transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Lapine T-Lymphocyte Immune Globulin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (PTIS, HCT)</arm_group_label>
    <other_name>Anti-Thymocyte Globulin Rabbit</other_name>
    <other_name>Grafalon</other_name>
    <other_name>Rabbit Anti-Human Thymocyte Globulin (RATG)</other_name>
    <other_name>Rabbit Anti-Thymocyte Globulin</other_name>
    <other_name>Rabbit Antithymocyte Globulin</other_name>
    <other_name>Rabbit ATG</other_name>
    <other_name>rATG</other_name>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Treatment (PTIS, HCT)</arm_group_label>
    <other_name>CellCept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Plasmapheresis</intervention_name>
    <description>Undergo plasmapheresis</description>
    <arm_group_label>Treatment (PTIS, HCT)</arm_group_label>
    <other_name>Plasma Exchange</other_name>
    <other_name>Therapeutic Plasma Exchange</other_name>
    <other_name>Therapeutic Plasmapheresis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (PTIS, HCT)</arm_group_label>
    <other_name>ABP 798</other_name>
    <other_name>BI 695500</other_name>
    <other_name>C2B8 Monoclonal Antibody</other_name>
    <other_name>Chimeric Anti-CD20 Antibody</other_name>
    <other_name>CT-P10</other_name>
    <other_name>IDEC-102</other_name>
    <other_name>IDEC-C2B8</other_name>
    <other_name>IDEC-C2B8 Monoclonal Antibody</other_name>
    <other_name>MabThera</other_name>
    <other_name>Monoclonal Antibody IDEC-C2B8</other_name>
    <other_name>PF-05280586</other_name>
    <other_name>Rituxan</other_name>
    <other_name>Rituximab ABBS</other_name>
    <other_name>Rituximab Biosimilar ABP 798</other_name>
    <other_name>Rituximab Biosimilar BI 695500</other_name>
    <other_name>Rituximab Biosimilar CT-P10</other_name>
    <other_name>Rituximab Biosimilar GB241</other_name>
    <other_name>Rituximab Biosimilar IBI301</other_name>
    <other_name>Rituximab Biosimilar JHL1101</other_name>
    <other_name>Rituximab Biosimilar PF-05280586</other_name>
    <other_name>Rituximab Biosimilar RTXM83</other_name>
    <other_name>Rituximab Biosimilar SAIT101</other_name>
    <other_name>Rituximab Biosimilar SIBP-02</other_name>
    <other_name>rituximab biosimilar TQB2303</other_name>
    <other_name>rituximab-abbs</other_name>
    <other_name>RTXM83</other_name>
    <other_name>Truxima</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Treatment (PTIS, HCT)</arm_group_label>
    <other_name>FK 506</other_name>
    <other_name>Fujimycin</other_name>
    <other_name>Hecoria</other_name>
    <other_name>Prograf</other_name>
    <other_name>Protopic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients 2-30 years-of-age with confirmed sickle cell disease (SCD) (SS &amp; sickle beta&#xD;
             [SB]-thalassemia, both sickle beta 0 [SB0] and sickle beta plus [SB+]) or severe&#xD;
             B-thalassemia major are potentially eligible&#xD;
&#xD;
          -  Patients with SCD should also meet the following eligibility criteria as outlined by&#xD;
             the Center for Medicaid and Medicare Services: sickle cell disease and at least one of&#xD;
             the following:&#xD;
&#xD;
               -  Stroke or neurological deficit lasting &gt; 24 hours&#xD;
&#xD;
               -  Recurrent acute chest syndrome (ACS): 2 or more episodes of ACS in 2-year period&#xD;
                  preceding enrollment&#xD;
&#xD;
               -  Recurrent vaso-occlusive pain crises: 3 or more episodes per year in 2-year&#xD;
                  period preceding enrollment or recurrent priapism (3 or more episodes in the 2&#xD;
                  years preceding enrollment)&#xD;
&#xD;
               -  Chronic transfusion program defined as 8 or more packed red blood cells (PRBC)&#xD;
                  transfusions per year to prevent central nervous system and/or vaso-occlusive&#xD;
                  complications in 1-year period preceding enrollment&#xD;
&#xD;
               -  Impaired neuropsychological function and abnormal cerebral magnetic resonance&#xD;
                  imaging (MRI) scan (silent strokes)&#xD;
&#xD;
               -  Stage I or II sickle lung disease&#xD;
&#xD;
               -  Sickle nephropathy (moderate or severe proteinuria or a glomerular filtration&#xD;
                  rate 30-50% of predicted normal value)&#xD;
&#xD;
               -  Bilateral proliferative retinopathy and major visual impairment in at least one&#xD;
                  eye&#xD;
&#xD;
               -  Osteonecrosis of multiple joints&#xD;
&#xD;
               -  Echocardiographic finding of tricuspid valve regurgitant jet velocity (TRJV) &gt;=&#xD;
                  2.7 m/sec&#xD;
&#xD;
          -  Patients with B-thalassemia are considered as severe if they are/have any of the&#xD;
             following:&#xD;
&#xD;
               -  Transfusion-dependent&#xD;
&#xD;
               -  Evidence of extra-medullary hematopoiesis&#xD;
&#xD;
               -  Pesaro Class III&#xD;
&#xD;
          -  Patients shall not proceed to HCT without confirmation of primary diagnosis by review&#xD;
             of available newborn screening results or hemoglobin electrophoresis and/or genetic&#xD;
             testing&#xD;
&#xD;
          -  DONOR: High resolution HLA typing will be performed on all willing and available&#xD;
             biologic parents and siblings without clinically significant hemoglobinopathy.&#xD;
             Preference will be given to donors with the lowest number of HLA-allele mismatches&#xD;
&#xD;
          -  DONOR: Donor-specific anti-HLA antibodies will be obtained and analyzed from all&#xD;
             patients. Preference will be given to donors with absent or low titer anti HLA-donor&#xD;
             specific antibody levels when possible&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled infection&#xD;
&#xD;
          -  Females who are pregnant and/or unwilling to cease breastfeeding&#xD;
&#xD;
          -  Seropositivity for human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Lansky or Karnofsky performance status &lt; 70%&#xD;
&#xD;
          -  Life expectancy severely limited by concomitant illness&#xD;
&#xD;
          -  Uncontrolled arrhythmias or symptomatic cardiac disease&#xD;
&#xD;
          -  Uncontrolled symptomatic pulmonary disease&#xD;
&#xD;
          -  Evidence of chronic active hepatitis or cirrhosis&#xD;
&#xD;
          -  Serum conjugated (direct) bilirubin &gt; 2 x upper limit of normal for age. Participants&#xD;
             are not excluded if the serum conjugated (direct) bilirubin is &gt; 2 x the upper limit&#xD;
             of normal for age as per local laboratory and:&#xD;
&#xD;
               -  There is evidence of a hyperhemolytic reaction after a recent red blood cell&#xD;
                  (RBC) transfusion, OR&#xD;
&#xD;
               -  There is evidence of moderate direct hyperbilirubinemia defined as direct serum&#xD;
                  bilirubin &lt; 5 times upper limit of normal (ULN) and not caused by underlying&#xD;
                  hepatic disease&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) &gt; 5 x upper limit&#xD;
             of normal for age&#xD;
&#xD;
          -  Serum creatinine &gt; 1.5 x upper limit of normal for age AND estimated or measure&#xD;
             creatinine clearance &lt; 70 mL/min/1.72 m^2&#xD;
&#xD;
          -  Patient, parent or guardian unable/unwilling to provide consent and when indicated,&#xD;
             assent&#xD;
&#xD;
          -  Patients with available HLA-matched related donor&#xD;
&#xD;
          -  Prior receipt of gene therapy&#xD;
&#xD;
          -  DONOR: All potential donors shall be tested by hemoglobin electrophoresis. Any&#xD;
             potential donor with a clinically significant hemoglobinopathy will be deemed&#xD;
             ineligible. Donors with sickle cell trait and beta thalassemia trait are eligible to&#xD;
             donate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kris M Mahadeo</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kris M Mahadeo</last_name>
    <phone>713-729-2873</phone>
    <email>kmmahadeo@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kris M. Mahadeo</last_name>
      <phone>713-729-2873</phone>
    </contact>
    <investigator>
      <last_name>Kris M. Mahadeo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 8, 2021</study_first_submitted>
  <study_first_submitted_qc>February 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2021</study_first_posted>
  <last_update_submitted>March 10, 2021</last_update_submitted>
  <last_update_submitted_qc>March 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>beta-Thalassemia</mesh_term>
    <mesh_term>Hemoglobinopathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

